# HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer

> **NCT04523896** · PHASE2 · UNKNOWN · sponsor: **David Büchser** · enrollment: 50 (estimated)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **RADIATION:** Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy

## Key facts

- **NCT ID:** NCT04523896
- **Lead sponsor:** David Büchser
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-01
- **Primary completion:** 2021-07
- **Final completion:** 2023-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523896, "HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04523896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*